Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

BACKGROUND: Macular edema secondary to retinal vein occlusion (RVO) is an important cause of loss of vision. Intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) are the standard of care in this disease, as shown in numerous randomized controlled trials. The purpose of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayanan, Raja, Kelkar, Aditya, Abbas, Zahir, Goel, Neha, Soman, Manoj, Naik, Naveen, Sudhalkar, Aditya, Walinjkar, Jaydeep, Shah, Utkarsh, Maksane, Nitin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805171/
https://www.ncbi.nlm.nih.gov/pubmed/33435908
http://dx.doi.org/10.1186/s12886-020-01757-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805171/
https://www.ncbi.nlm.nih.gov/pubmed/33435908
http://dx.doi.org/10.1186/s12886-020-01757-7

Ejemplares similares